Relief for MS patients as drug added to PBS
Some 800 patients a year are expected to benefit from siponimod's listing that takes effect on 1 November
Patients with secondary progressive MS will have their annual medication bill slashed from $25,000 a year, under the latest PBS additions.
From 1 November, siponimod (Mayzent®) will be listed on the PBS to treat those patients with secondary progressive MS under the $86 million commitment over the next four years.
Without the PBS subsidy, these patients would pay more than $25,000 per year for treatment, with some 800 patients benefiting from its listing each year.
Patients will only need to pay $41 per prescription — or $6.60 with a concession card — under the PBS subsidy.
